Add-on IVIG therapy effective for some severe AIHA patients: Study
A third of adults with severe autoimmune hemolytic anemia (AIHA) — a group of rare conditions that includes cold agglutinin disease (CAD) — responded to intravenous immunoglobulins (IVIG), when used as an add-on therapy, after seven days, according to a retrospective study from France. The study also detailed a…